Freeline_Logo_Red_RGB.jpg
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET | Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
Freeline_Logo_Red_RGB.jpg
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET | Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
May 24, 2022 08:00 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Freeline_Logo_Red_RGB.jpg
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022 16:01 ET | Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline_Logo_Red_RGB.jpg
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
May 02, 2022 17:10 ET | Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Full Year 2021 Financial Results and Business Highlights
March 31, 2022 16:01 ET | Freeline Therapeutics
Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Companythrough key data readouts across...
Freeline_Logo_Red_RGB.jpg
Freeline to Participate in Upcoming Investor Conferences
March 23, 2022 07:00 ET | Freeline Therapeutics
LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that senior management will participate in the following...
Freeline_Logo_Red_RGB.jpg
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
March 09, 2022 07:44 ET | Freeline Therapeutics
On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE)...
Freeline_Logo_Red_RGB.jpg
Freeline To Participate In Conferences During January 2022
January 04, 2022 16:01 ET | Freeline Therapeutics
LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative...
Freeline_Logo_Red_RGB.jpg
Freeline Announces 2022 Corporate Priorities and Guidance
December 13, 2021 17:40 ET | Freeline Therapeutics
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform Data...